SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    P. G. Richardson, W. Xie, S. Jagannath, A. Jakubowiak, S. Lonial, N. S. Raje, M. Alsina, I. M. Ghobrial, R. L. Schlossman, N. C. Munshi, A. Mazumder, D. H. Vesole, J. L. Kaufman, K. Colson, M. McKenney, L. E. Lunde, J. Feather, M. E. Maglio, D. Warren, D. Francis, T. Hideshima, R. Knight, D.-L. Esseltine, C. S. Mitsiades, E. Weller, K. C. Anderson, A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma, Blood, 2014, 123, 10, 1461

    CrossRef

  2. 2
    Natalie Callander, Stephanie Markovina, Jens Eickhoff, Paul Hutson, Toby Campbell, Peiman Hematti, Ronald Go, Robert Hegeman, Walter Longo, Eliot Williams, Fotis Asimakopoulos, Shigeki Miyamoto, Acetyl-l-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network, Cancer Chemotherapy and Pharmacology, 2014, 74, 4, 875

    CrossRef

  3. 3
    H. Ludwig, H. Kasparu, C. Leitgeb, E. Rauch, W. Linkesch, N. Zojer, R. Greil, A. Seebacher, L. Pour, A. Weissmann, Z. Adam, Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma, Blood, 2014, 123, 7, 985

    CrossRef

  4. 4
    Sebastian Grosicki, Agnieszka Barchnicka, Artur Jurczyszyn, Anida Grosicka, Bortezomib for the treatment of multiple myeloma, Expert Review of Hematology, 2014, 7, 2, 173

    CrossRef

  5. 5
    Jae-Sook Ahn, Sung-Hoon Jung, Seung-Shin Lee, Seo-Yeon Ahn, Deok-Hwan Yang, Yeo-Kyeoung Kim, Hyeoung-Joon Kim, Je-Jung Lee, Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma, BioMed Research International, 2014, 2014, 1

    CrossRef

  6. 6
    Jacob P Laubach, Peter M Voorhees, Hani Hassoun, Andrzej Jakubowiak, Sagar Lonial, Paul G Richardson, Current strategies for treatment of relapsed/refractory multiple myeloma, Expert Review of Hematology, 2014, 7, 1, 97

    CrossRef

  7. 7
    Andrew M. Evens, Mitchell R. Smith, Izidore S. Lossos, Irene Helenowski, Michael Millenson, Jane N. Winter, Steve T. Rosen, Leo I. Gordon, Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study, British Journal of Haematology, 2014, 166, 4
  8. 8
    Heinrich J. Huber, Ross G. McKiernan, Jochen H. M. Prehn, Harnessing system models of cell death signalling for cytotoxic chemotherapy: towards personalised medicine approaches?, Journal of Molecular Medicine, 2014, 92, 3, 227

    CrossRef

  9. 9
    H Ludwig, J S Miguel, M A Dimopoulos, A Palumbo, R Garcia Sanz, R Powles, S Lentzsch, W Ming Chen, J Hou, A Jurczyszyn, K Romeril, R Hajek, E Terpos, K Shimizu, D Joshua, V Hungria, A Rodriguez Morales, D Ben-Yehuda, P Sondergeld, E Zamagni, B Durie, International Myeloma Working Group recommendations for global myeloma care, Leukemia, 2014, 28, 5, 981

    CrossRef

  10. 10
    Denise Niewerth, Gerrit Jansen, Yehuda G. Assaraf, Sonja Zweegman, Gertjan L. Kaspers, Jacqueline Cloos, Molecular basis of resistance to proteasome inhibitors in hematological malignancies, Drug Resistance Updates, 2014,

    CrossRef

  11. 11
    S E Assouline, J Chang, B D Cheson, R Rifkin, S Hamburg, R Reyes, A-M Hui, J Yu, N Gupta, A Di Bacco, Y Shou, P Martin, Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma, Blood Cancer Journal, 2014, 4, 10, e251

    CrossRef

  12. 12
    Anna Guidetti, Claudia Paba Prada, Jacob P Laubach, Cindy Varga, Michelle E Maglio, Mary McKenney, Deborah Doss, Robert L Schlossman, Constantine Mitsiades, Teru Hideshima, Güllü T Görgün, Irene M Ghobrial, Noopur Raje, Nikhil Munshi, Kenneth C Anderson, Paul G Richardson, Pomalidomide for the treatment of relapsed and refractory multiple myeloma, Expert Opinion on Orphan Drugs, 2014, 2, 10, 1089

    CrossRef

  13. 13
    Massimo Offidani, Laura Corvatta, Patrizia Caraffa, Pietro Leoni, Chiara Pautasso, Alessandra Larocca, Antonio Palumbo, Pomalidomide for the treatment of relapsed–refractory multiple myeloma: a review of biological and clinical data, Expert Review of Anticancer Therapy, 2014, 14, 5, 499

    CrossRef

  14. 14
    Silvia Gentili, Sagar Lonial, Relapsed and Refractory Multiple Myeloma, Hematology/Oncology Clinics of North America, 2014, 28, 5, 861

    CrossRef

  15. 15
    J R Berenson, J D Hilger, O Yellin, R Dichmann, D Patel-Donnelly, R V Boccia, A Bessudo, L Stampleman, D Gravenor, S Eshaghian, Y Nassir, R A Swift, R A Vescio, Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy, Leukemia, 2014, 28, 7, 1529

    CrossRef

  16. 16
    Axel Vater, Sven Klussmann, Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer® therapeutics, Drug Discovery Today, 2014,

    CrossRef

  17. 17
    Elizabeth A. Kuczynski, Daniel J. Sargent, Axel Grothey, Robert S. Kerbel, Drug rechallenge and treatment beyond progression—implications for drug resistance, Nature Reviews Clinical Oncology, 2013, 10, 10, 571

    CrossRef

  18. 18
    M Offidani, L Corvatta, L Maracci, A M Liberati, S Ballanti, I Attolico, P Caraffa, F Alesiani, T Caravita di Toritto, S Gentili, P Tosi, M Brunori, D Derudas, A Ledda, A Gozzetti, C Cellini, L Malerba, A Mele, A Andriani, S Galimberti, P Mondello, S Pulini, U Coppetelli, P Fraticelli, A Olivieri, P Leoni, Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study, Blood Cancer Journal, 2013, 3, 11, e162

    CrossRef

  19. 19
    Lisa J. Crawford, Alexandra E. Irvine, Targeting the ubiquitin proteasome system in haematological malignancies, Blood Reviews, 2013, 27, 6, 297

    CrossRef

  20. 20
    Kristen M Sanfilippo, Ravi Vij, Current & Emerging Therapeutics for Multiple Myeloma, 2013,

    CrossRef